Regeneron Pharmaceuticals (REGN) Downgraded to “Neutral” at Robert W. Baird

Posted on by

REGN has been the subject of a number of other reports. Canaccord Genuity reaffirmed a “$367.74” rating and issued a $304.00 price target on shares […]

Read the original post by AmericanBankingNews.com